Amicus Therapeutics, Inc. (FOLD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$14.49
Price Target
$14.50
Target Range
$14.50 — $14.50
Analyst Rating
Buy
Forward P/E40.6x
Trailing P/E-80.5x
Forward PEG—
Implied Growth+887.4%
Median Target$14.50
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$15
+0.1%
Consensus
$15
+0.1%
Bull Case
$15
+0.1%
FOLD Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Amicus Therapeutics, Inc. (FOLD) has a Wall Street consensus price target of $14.50, based on estimates from 24 covering analysts. With the stock currently trading at $14.49, this represents a potential upside of +0.1%. The company has a market capitalization of $4.47B.
Analyst price targets range from a low of $14.50 to a high of $14.50, representing a 0% spread in expectations. The median target of $14.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FOLD trades at a trailing P/E of -80.5x and forward P/E of 40.6x. Analysts expect EPS to grow +887.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+39.4%
Avg Forward P/E23.5x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.01 | $51.50 | +105.9% | Buy | — | 33 |
 SRPTSarepta Therapeutics, Inc. | $2.3B | $21.79 | $24.63 | +13.0% | Buy | 7.3x | 54 |
 BMRNBioMarin Pharmaceutical Inc. | $10.2B | $53.24 | $89.64 | +68.4% | Buy | 12.4x | 41 |
 IONSIonis Pharmaceuticals, Inc. | $12.4B | $75.25 | $107.27 | +42.6% | Buy | — | 32 |
 KRYSKrystal Biotech, Inc. | $8.4B | $284.57 | $332.75 | +16.9% | Buy | 37.7x | 17 |
 ACADACADIA Pharmaceuticals Inc. | $3.8B | $22.35 | $34.78 | +55.6% | Buy | 50.4x | 37 |
 PTCTPTC Therapeutics, Inc. | $5.4B | $65.04 | $89.67 | +37.9% | Buy | — | 26 |
 LGNDLigand Pharmaceuticals Incorporated | $4.6B | $232.30 | $267.75 | +15.3% | Buy | 26.1x | 17 |
 IQVIQVIA Holdings Inc. | $29.9B | $176.42 | $225.63 | +27.9% | Buy | 13.9x | 44 |
 CRLCharles River Laboratories International, Inc. | $9.1B | $185.39 | $205.43 | +10.8% | Buy | 16.7x | 36 |
Upside Potential Comparison
RAREBMRNACADIONSPTCTIQVKRYSLGNDSee FOLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FOLD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FOLD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
What is the FOLD stock price target for 2026?
The consensus price target for FOLD is $14.5, close to the current price of $14.49 (0.1% implied move). Based on 24 analyst estimates, the stock appears fairly valued near current levels.
Is FOLD a buy, sell, or hold?
FOLD has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $14.5 implies 0.1% upside from current levels.
Is FOLD stock overvalued or undervalued?
At a forward P/E of 40.6224x, FOLD trades at a premium valuation. The consensus price target of $14.5 (0.1% upside) suggests analysts may view current valuations as stretched.
How high can FOLD stock go?
The most bullish Wall Street analyst has a price target of $14.5 for FOLD, while the most conservative target is $14.5. The consensus of $14.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover FOLD stock?
FOLD is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the FOLD stock forecast?
The 12-month FOLD stock forecast based on 24 Wall Street analysts shows a consensus price target of $14.5, with estimates ranging from $14.5 (bear case) to $14.5 (bull case). The median consensus rating is "Buy".
What is FOLD's forward P/E ratio?
FOLD trades at a forward P/E ratio of 40.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy FOLD stock?
FOLD appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $14.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do FOLD price targets vary so much?
FOLD analyst price targets range from $14.5 to $14.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14.5 consensus represents the middle ground.